Jun Tanaka
Daiichi Sankyo
16 Papers
213 Citations
Jun Tanaka is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Prodrug & Peroxisome proliferator-activated receptor. The author has an hindex of 8, co-authored 16 publications. Previous affiliations of Jun Tanaka include Hokkaido University.
Chat about Author
Papers
Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver.
Kazuyuki Tobe,Ryo Suzuki,Masashi Aoyama,Toshimasa Yamauchi,Junji Kamon,Naoto Kubota,Yasuo Terauchi,Junji Matsui,Yasuo Akanuma,Satoshi Kimura,Jun Tanaka,Manabu Abe,Jun Ohsumi,Ryozo Nagai,Takashi Kadowaki +14 more
TL;DR: In this paper, the sterol regulatory element-binding protein (SREBP)-1 gene, a downstream target of insulin, was paradoxically increased in 16-week-old IRS-2−/− mouse liver, where insulin-mediated intracellular signaling events were substantially attenuated.
141
Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Taishi Yoshida,Akira Okuno,Jun Tanaka,Kanako Takahashi,Ryutaro Nakashima,Shoichi Kanda,Junko Ogawa,Yuka Hagisawa,Toshihiko Fujiwara +8 more
TL;DR: It is confirmed that metformin primarily decreases plasma glucose not by gluconeogenesis inhibition but by activating glucose utilization in GK rats, which may have implications for met formin and CS-917 in the treatment of type 2 diabetes patients.
29
Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators.
Takashi Tsuji,Mitsuhiro Yamaguchi,Junichi Kuroyanagi,Shinji Furuzono,Masahiro Konishi,Koji Terayama,Jun Tanaka,Motoko Saito,Yoshiyuki Kobayashi +8 more
TL;DR: Promising compound 26b showed a significant blood glucose lowering effect in the severe diabetic mice model (10-week aged db/db mice) after oral dosing even at 10 mg/kg, implying that the pyridazine derivatives have potential to become novel therapeutic agents for diabetes mellitus.
23
Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor γ ligand, Cerco-A
Kenji Wakabayashi,Shinko Hayashi,Yumi Matsui,Takuo Matsumoto,Akihiro Furukawa,Masanori Kuroha,Naomi Tanaka,Tomoko Inaba,Shoichi Kanda,Jun Tanaka,Ryo Okuyama,Satoko Wakimoto,Tsuneaki Ogata,Kazushi Araki,Jun Ohsumi +14 more
TL;DR: Cerco-A offers beneficial effects on glycemic control with attenuated undesirable side effects and had significantly lower effects on heart and white adipose tissues weight gain.
19
Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.
Akihiro Furukawa,Tsuyoshi Arita,Takehiro Fukuzaki,Makoto Mori,Takeshi Honda,Susumu Satoh,Yumi Matsui,Kenji Wakabayashi,Shinko Hayashi,Kouichi Nakamura,Kazushi Araki,Masanori Kuroha,Jun Tanaka,Satoko Wakimoto,Osamu Suzuki,Jun Ohsumi +15 more
TL;DR: Oral administration of the potassium salt of compound 15 remarkably improved the plasma glucose levels of female Zucker diabetic fatty rats at 1 mg/kg and did not cause a plasma volume increase or a cardiac enlargement in Wistar-Imamichi rats, even at 100mg/kg.
15